# OH2 Injection in Melanoma

> **NCT05868707** · PHASE3 · RECRUITING · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 340 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** OH2
- **DRUG:** Salvage chemotherapy or best supportive care

## Key facts

- **NCT ID:** NCT05868707
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868707, "OH2 Injection in Melanoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05868707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*